PMV Pharma gets a whopping $74M round to test a new p53 drug in humans
Mutant p53 proteins have been one of the biggest — and most frustrating — targets in biotech. But an upstart in Cranbury, NJ has landed a whopping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
